Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)

This study has been completed.
Celgene Corporation
Information provided by:
PETHEMA Foundation Identifier:
First received: May 28, 2007
Last updated: July 30, 2013
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):